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Lack of association between endothelial nitric oxide synthase 
glu298Asp variation, visceral obesity and insulin related 
phenotypes in Turkish type 2 diabetic patients
Burcu Bayoglu1, Melike Ersoz2, Penbe Cagatay3, Cavlan Ciftci4, Belgin Süsleyici Duman5
Nitric oxide (NO) is an endothelium derived relaxing factor 
(EDRF) important in regulating heart-vessel physiology. The 
objective of this study �as to investigate �hether the eNOS 
gene Glu298Asp variation influenced the lipid parameters, 
visceral obesity, insulin related phenotypes and type 2 diabe-
tes mellitus (T2DM) development, for the first time in a Turk-
ish study group. We analyzed the the eNOS gene Glu298Asp 
genotype frequencies in 115 type 2 diabetic and 68 healthy 
control subjects. Serum lipids and insulin-related phenotypes 
�ere also analyzed. No significant difference for genotypic 
frequencies �as observed for the Ban II (Eco241) restric-
tion site in T2DM patients as compared to controls. eNOS 
Glu298Asp polymorphism �as not found to affect visceral 
obesity and insulin related phenotypes. Ho�ever,  T2DM pa-
tients �ith Asp/Asp genotype �ere found to have lo�er he-
patic insulin sensitivity (HIS) in comparison to Glu/Glu. In 
healthy controls, the insulin and HOMA levels �ere found 
to be lo�er in Glu/Asp genotype �ith respect to Glu/Glu 
genotype carriers (p>0.05). In T2DM patients, visceral obe-
sity �as observed in higher frequencies �ith Asp/Asp geno-
type, in comparison to Glu/Glu genotype. eNOS Glu298Asp 
polymorphism �as not found to affect serum lipid levels in 
the T2DM group. Ho�ever in the control group, lo�er serum 
apoB levels �ere observed in Asp/Asp genotype carriers in 
comparison to Glu/Glu genotype (p ≤ 0.05). The eNOS gene 
Glu298Asp polymorphism �as not found to be associated 
�ith T2DM in the present study group. Although not sig-
nificant, since the eNOS Glu298Asp genotypes �ere found to 
be related to HIS, insulin, HOMA and visceral obesity in the 
present study, further studies on larger samples are needed to 
explore the exact role of eNOS Glu298Asp polymorphism in 
insulin related phenotypes and visceral obesity.
Key words: Glu298Asp polymorphism, Type 2 diabetes, eNOS, 
Hepatic insulin sensitivity, β-cell index.
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Introduction
Type 2 diabetes mellitus (T2DM) is a hetero-
geneous disorder that develops in response 
to both genetic and environmental factors 
(1). The predisposition to T2DM is thought 
to be conferred by a number of different 
genes that in isolation may have minor ef-
fects, but in combination lead to the charac-
teristic pathophysiological condition (2). 
Nitric oxide (NO) is synthesized from 
L-Arginine by nitric oxide synthase (NOS). 
NOS has three isoforms; neuronal (nNOS), 
induced (iNOS), and endothelial (eNOS). 
eNOS is the only isoform constitutively syn-
thesized both in vivo and in vitro (3). Argi-
nine deficiency is a rare occurrence, ho�ev-
er, there can be competitive inhibition by the 
endogenously produced asymmetrical di-
methylarginine (ADMA) and nitroarginine. 
ADMA is emerging as an important cause 
of endothelial cell dysfunction. The relative 
deficiency of L-arginine due to elevation of 
ADMA levels contributes to oxidative stress 
and results in the atheroscleropathy associ-
ated �ith insulin resistance, metabolic syn-
drome, prediabetes and overt T2DM (4).
Genetic polymorphisms of eNOS have 
been sho�n to have a significant effect on 
NO levels, plasma lipids and have been as-
sociated �ith T2DM (5), heart failure (6), 
coronary spasm (7), atherosclerosis (8), 
myocardial infarction (9) and hypertension 
(9) in some studies. Several studies have 
reported restriction fragment length poly-
morphisms (RFLP) of eNOS Glu298Asp to 
be associated �ith type 2 diabetes �hile oth-
ers did not find such an association (5, 10, 
11). Glu298Asp polymorphism of the eNOS 
gene is caused by a base substitution  (G→T) 
in the position 894 of the exon 7, changing 
Glutamic acid to Aspartic acid (12).
Since the contribution of eNOS gene 
polymorphisms to the development of type 
2 diabetes differ among populations, the aim 
of the present study �as to evaluate the fre-
quency distributions of eNOS Glu298Asp 
genotypes in Turkish patients �ith T2DM 
as compared to controls. Also the influence 
of Glu298Asp polymorphism over lipid pa-
rameters, visceral obesity, insulin related 
phenotypes together �ith their association 
�ith type 2 diabetes �as evaluated.
Methods
Population sample
We studied 115 unrelated type 2 diabetic pa-
tients (67 men and 48 �omen; age: 58.24 ± 
0.94 years). The patients �ere recruited from 
Caglayan Florence Nightingale Hospital (Is-
tanbul, Turkey). Age at diabetes onset �as 
45.05 ± 11.85 years. Type 2 diabetic patients 
�ere selected according to WHO criteria 
(13). Of the 115 type 2 diabetic patients, 64 
�ere treated �ith sulphonylurea drugs, 38 
�ith metformin and 13 �ith sulphonylurea 
drugs in combination �ith metformin. The 
study protocol �as approved by the Ethics 
Committee of the �adir Has University, Fac-
ulty of Medicine, and informed consent �as 
obtained from each participant. The control 
group consisted of 68 unrelated healthy in-
dividuals (47 men and 21 �omen; age: 55.31 
± 1.47 years) �ithout medication, �ho at-
tended a routine health check at a general 
practice in Caglayan Florence Nightingale 
Hospital (Istanbul, Turkey). The hepatic and 
endocrine functions of the patients �ere 
normal and all �ere relatively �ell controlled 
�ith glycosylated hemoglobin (HbA1c) ≤ 7% 
(normal range ≤ 8%). Patients �ith macro- 
and microangiopathic complications �ere 
excluded from the study. No member of the 
sample populations admitted to alcohol in-
take and none had a history of smoking.
Clinical and biochemical evaluation
Blood samples �ere collected after overnight 
(>12h) fasting. The biochemical analysis in-
cluded determination of fasting plasma glu-
cose, insulin, HbA1c, hepatic insulin sensi-
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tivity (HIS), index of β-cell secretory force 
(HOMA), total cholesterol (T-Chol), triac-
ylglycerol (TAG), apolipoprotein E (apo E), 
apolipoprotein A1 (apo A1) and apolipopro-
tein B (apo B). Serum TAG and T-Chol lev-
els �ere measured using standard enzymatic 
methods (Merck, Darmstadt, Germany), au-
tomated on an AU5021 (Olympus, Merck). 
Serum apo E �as determined by turbidim-
etry automated on a Cobas-Mira analyzer 
(Roche, Meylan, France); serum apo A1 and 
apo B �ere determined by immunoneph-
elometry on a Behring Nephelometer ana-
lyzer �ith Behring reagents (Behring�erke, 
Marburg, Germany). Sera �ere analyzed 
�ithout pretreament and diluted in double-
distilled �ater �hen lipid or apolipoprotein 
levels exceeded reference values.
Anthropometric measurements 
Body mass index (BMI)
The body mass index (BMI) �as calculated 
and over�eight (obese) �as defined as a val-
ue ≥ 25 kg/m2 (14).
Waist to hip circumference ratio (WHCR)
Waist circumference �as measured at the 
level of the umbilicus �hile the subject �as 
standing and breathing normally. Hip cir-
cumference �as measured at the level of 
greatest hip girth. All participants �ere ac-
cepted as abdominal (visceral) obese, since 
their WHCR �ere greater than 0.95 and 1.0 
for females and males, respectively.
Pancreatic β–cell secretory capacity
Pancreatic β–cell secretory capacity �as esti-
mated by β–index (index of β–cell secretory 
force; HOMA β–cell index) by the formula 
proposed by Hosker et al. (15), HOMA β–
cell index= 20 × insulinF / (glucoseF –3.5).
Hepatic insulin sensitivity
Hepatic insulin sensitivity �as assessed by 
the follo�ing formulas realized by Matsuda 
and De Fronzo (16): Hepatic insulin sensi-
tivity (HIS) = k/ (GF x IF) (k = 22.5x 18=405; 
GF and  IF, fasting plasma glucose (mg/dl) 
and insulin (μU/ml), respectively).
Molecular analysis
Genomic DNA �as extracted from leuko-
cytes by a salting out procedure (17). The 
desired segments �ere amplified by PCR 
(18) using the eNOS Ban II (Eco241) pro-
tocol �ith primers (Integrated DNA Tech-
nologies, IDT, USA):  298F: 5’–GAC CCT 
GGA GAT GAA GGC AGG AGA–3’ and 
298R: 5’–ACC ACC AGG ATG TTG TAG 
CGG TGA–3’. The final 248 bp amplification 
products produce 163 bp and 85 bp prod-
ucts for the Glu298 allele, but fails to cleave 
the 248 bp fragment containing the Asp298 
allele after digestion �ith Ban II. Restricted 
products �ere visualized on 2% agarose gel. 
Statistical analysis
Statistical analyses �ere conducted using 
the Unistat 5.1 soft�are program. Data �ere 
expressed as means ± SE. Baseline differ-
ences bet�een patients and controls �ere 
examined by Student t-test. Hardy-Wein-
berg equilibrium for genotype frequencies 
�as estimated by the Chi-square test. The 
variables across the various genotypes and 
groups �ere estimated by t�o �ay ANOVA 
�ith an interaction term to test the influence 
of eNOS Glu298Asp genotypes on analyzed 
parameters. The Bonferroni correction for 
multiple testing �as applied to T2DM and 
control groups separately as required. P values 
less than 0.05 �ere considered significant.
Results
The genotype frequency distributions of 
the 115 type 2 diabetic and 68 control sub-
jects �ith respect to Glu298Asp polymor-
phism �ere compared (Table 1). 
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Table 1  eNOS Glu298Asp genotype frequencies  
in type 2 diabetic patients and control subjects
eNOS Glu298Asp Genotype frequencies
Glu/Glu; n (%) Glu/Asp; n (%) Asp/Asp; n (%)
Diabetic 15 (13 .0) 43 (37 .4) 57 (49 .6)
Control 11 (16 .2) 29 (42 .6) 28 (41 .2)
Results are expressed as numbers (per-
centage). The eNOS genotype frequencies of 
the control and diabetic groups �ere com-
pared �ith Chi-square test and no signifi-
cance �as found (χ2 = 0.243, p = 0.537).
The eNOS gene Glu298Asp polymor-
phism frequencies for Glu/Glu, Glu/Asp 
and Asp/Asp genotypes �ere respectively 
13%, 37.4%, 49.6% in subjects �ith type 2 
diabetes and 16.2%, 42.6%, 41.2% in the 
control group. No significant difference �as 
observed in genotype frequencies bet�een 
the type 2 diabetic and control groups (χ2 = 
1.243, p = 0.537). When the demographic 
characteristics of the study subjects, to-
gether �ith the eNOS Glu298Asp geno-
type effect and group genotype interaction 
�ere examined no significant difference 
�as observed for any analyzed character-
istic �hen the diabetic and control groups 
�ere compared (data not included). Also 
no significant effect of eNOS genotypes �as 
found over the demographic parameters. 
The clinical characteristics of the study sub-
jects are compared as a function of groups 
and eNOS genotypes. In detail, insulin (p ≤ 
0.001), HbA1c (p ≤ 0.001), fasting glucose 
(p ≤ 0.001) and β-cell index (p ≤ 0.001) 
�ere significantly higher in diabetic patients 
compared to controls, �hereas HIS (p ≤ 
0.001) �as higher in controls. No significant 
difference �as observed (p ≥ 0.05) for the T-
Chol, TAG, apo E, apo A1 and apo B levels 
�hen the diabetic and control groups �ere 
compared (data not included). The effects of 
the eNOS polymorphism on clinical or bio-
chemical characteristics �ere analyzed and 
not found to be significantly effective (data 
not included). The demographic and clinical 
parameters �ere compared bet�een eNOS 
Glu298Asp genotypes separately for type 2 
diabetic and control  groups (Table 2). 
Although no significant difference �as 
observed, T2DM patients �ith Asp/Asp gen-
otype �ere found to have lo�er HIS levels in 
comparison to Glu/Glu. In healthy controls, 
the insulin and HOMA levels �ere found to 
be lo�er in Glu/Asp genotype �ith respect to 
Glu/Glu genotype carriers (p > 0.05). Also, 
in T2DM patients �ith Asp/Asp genotype, 
visceral obesity �as found to be higher in 
comparison to the Glu/Glu genotype. None 
of the analyzed serum lipids �ere found to 
differ bet�een the eNOS Glu298Asp geno-
types in patients �ith T2DM (Table 2). In 
the control group, the demographic, clinical 
and biochemical parameters �ere not found 
to be different among eNOS Glu298Asp 
genotypes except for apo B levels. In detail, 
lo�er serum apo B levels �ere observed in 
the Asp/Asp genotype �hen compared to 
Glu/Glu genotype carriers (p ≤ 0.05).
Discussion
Multiple studies provide evidence that ge-
netic factors are important contributors to 
the inter-individual variation in diabetes 
susceptibility (19-21). The eNOS gene Glu-
298Asp polymorphism has been reported to 
decrease the basal NO production in healthy 
subjects (22). eNOS Glu298Asp polymor-
phism may interact �ith other gene poly-
morphisms of other endogenous antioxidant 
enzymes and especially environmental con-
ditions such as smoking,  obesity, toxicities 
of insulin resistance, metabolic syndrome 
and T2DM as �e kno� their antioxidant re-
serve is compromised (23–24). eNOS Glu-
298Asp polymorphism causes endothelial 
dysfunction, and thus oxidative stress, may 
be responsible for insulin resistance and 
T2DM (4). For this reason �e thought that 
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Glu298Asp variation may be responsible for 
T2DM. 
A limited number of studies have exam-
ined eNOS gene Glu298Asp polymorphism 
(5, 10, 11, 25) in patients �ith T2DM. Ac-
cording to our kno�ledge, only one study 
(5) has found an association bet�een eNOS 
Glu298Asp polymorphism and T2DM. In 
detail, Monti et al. (5) evaluated Glu298Asp 
polymorphism in exon 7 in 159 type 2 diabet-
ic patients �ithout macrovascular complica-
tions and in 207 healthy control subjects and 
described a significant association bet�een 
eNOS gene Glu298Asp polymorphism and 
T2DM. Monti et al. (5) suggested eNOS 
Glu298Asp polymorphism as a ne� genetic 
susceptibility factor for hyperinsulinemia, 
insulin resistance and T2DM.  In a study 
Table 2  Clinical characteristics of type 2 diabetic and control subjects with respect  
to eNOS gene Glu298Asp genotypes
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Values are represented as mean ± SE . BMI: body mass index . HbA1c: glycosylated hemoglobin . HIS: hepatic insulin sensitivity 
(= k / fasting insulin × fasting plasma glucose (where k = 22 .5 × 18= 405) . HOMA: homeostasis model assessment (= 20 × fast-
ing insulin / (fasting plasma glucose – 3 .5) . Ap ≤ 0 .05 Glu/Glu versus genotype in controls .
Burcu Bayoglu et al .: Endothelial Nitric Oxide Synthase Polymorphism and Type 2 Diabetes
96
from the United �ingdom (10), 152 SNPs in 
71 candidate genes �ere examined in 2134 
Caucasians, �here no association �as found 
bet�een eNOS Glu298Asp polymorphism 
and T2DM. Thameem et al. (25) investi-
gated �hether the T-786C, Glu298Asp and 
27bp-VNTR variants of the eNOS gene are 
associated �ith T2DM and its related traits 
in Mexican Americans and did not find Glu-
298Asp polymorphism as a significant con-
tributor to disease. Similar to Barroso et al. 
(10) and Thameem (25), �e �ere not able to 
demonstrate any association bet�een eNOS 
Glu298Asp polymorphism and T2DM in 
the present study. A possible explanation 
for the lack of relationship of polymorphism 
�ith disease in the present study may be 
that patients �ith gene polymorphism of the 
eNOS enzyme may be capable of �ithstand-
ing many years of redox stress before the de-
fect in eNOS becomes evident. 
The Glu298Asp allelic variation of the 
eNOS gene sho�s variations in different eth-
nic groups. Ukkola et al. (11) evaluated the 
presence of the Glu298Asp polymorphism 
in 239 Caucasian patients �ith T2DM �ith 
a high prevalence of macroangiopathy and 
245 control subjects, but did not find any 
significant difference in the allelic frequency 
bet�een the T2DM and the control groups. 
In 159 Caucasian T2DM patients �ithout 
macrovascular complications Monti et al. 
(5) reported Glu298Asp Glu/Glu, Glu/Asp 
and Asp/Asp genotype frequencies to be 
32.7%, 39.6% and 27.7%; �hereas in 207 
healthy control subjects they �ere 46.4%, 
39.6% and 14%. Monti et al. (5) found Glu-
298Asp genotype frequencies  significantly 
different among their study groups (χ2 = 1, 
p = 0.0005). In detail,  Asp/Asp genotype 
frequency �as higher in type 2 diabetic pa-
tients in comparison to controls. Thadeem 
et al. (25) evaluated 670 lo�-income Mexi-
can Americans �ith T2DM, and all first-, 
second- and third degree relatives. They 
reported Glu298Asp Glu/Glu, Glu/Asp and 
Asp/Asp genotype frequencies to be 65%, 
30% and 5% (25). In another study, Srivas-
tava et al. (26) reported Glu298Asp Glu/Glu, 
Glu/Asp, Asp/Asp genotype frequencies re-
spectively as, 71.22%, 28.06%, 0.72% in 139 
healthy Indians, and did not find any sig-
nificant difference bet�een the groups �ith 
respect to Glu298Asp genotypes. In our 
study the Glu/Glu, Glu/Asp and Asp/Asp 
genotype frequencies �ere respectively as 
13.0%, 37.4% 49.6 %for the diabetic group; 
and 16.2%, 42.6% and 41.2% for the control 
group. We did not find any significant differ-
ence bet�een the T2DM and control groups, 
�hen the frequency of eNOS genotypes �ere 
compared (χ2 = 1.243, p = 0.537). 
Monti et al. (5) �ere not able to find any 
difference in metabolic parameters (plasma 
glucose, BMI, TAG, systolic and diastolic 
blood pressure) except visceral obesity (�aist 
to hip ratio). They found visceral obesity 
much higher in Asp/Asp genotype carriers 
in comparison to Glu/Glu and Glu/Asp (5). 
In agreement �ith the results of Monti et al. 
(5), although not statistically significant, vis-
ceral obesity �as found to be higher in type 
2 diabetic patients �ith Asp/Asp genotype 
�hen compared to Glu/Glu in our study. 
Furthermore, Yoshimura et al. (27) sho�ed 
that Asp/Asp genotype lo�ered HIS levels 
in coronary artery disease. Interestingly, in 
our study �e observed that in type 2 diabetic 
patients the Asp/Asp genotype carriers had 
lo�er HIS levels �hen compared to Glu/Glu 
genotype carriers. Exercise induced skeletal 
muscle glucose transport (GLUT4) is eNOS 
dependent. If the production of eNO �ere 
defective due to gene polymorphism and 
environmental interaction there �ould be 
increasing peripheral insulin resistance (28-
30). Monti et al. (5) sho�ed that in healthy 
controls, Asp/Asp genotype carriers had 
higher insulin, C-peptide, NO, and HOMA 
levels compared to Glu/Glu genotype. In the 
present study, in healthy controls, the insulin 
and HOMA levels �ere found to be lo�er in 
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Glu/Asp genotype �ith respect to Glu/Glu 
genotype carriers. 
Paradossi et al. (31) evaluated Glu298Asp 
polymorphism in 118 healthy control sub-
jects and found no influence on lipid param-
eters. In the present study the Glu298Asp 
variant of the eNOS gene �as not found to 
be associated �ith the lipid parameters in 
the T2DM group. Ho�ever, Ukkola et al. 
(11) sho�ed that male diabetic patients �ith 
Asp/Asp genotype had higher plasma very-
lo� density lipoprotein (VLDL) cholesterol 
and VLDL-triacylglycerol concentrations 
than those �ith the genotypes Glu/Glu or 
Glu/Asp. In the present study �e found an 
association bet�een the presence of the Glu-
298Asp polymorphism of the eNOS gene and 
apo B levels in the control group. But �e did 
not find any association bet�een Glu298Asp 
variation and the clinical parameters in the 
T2DM group. 
Conclusion
There �as no significant difference in geno-
typic frequencies of the Glu298Asp polymor-
phism of the eNOS gene bet�een the T2DM 
and control groups. In the present study, the 
Glu298Asp polymorphism of the eNOS gene 
is not associated either �ith visceral obesity 
or �ith insulin related phenotypes in Turk-
ish samples �ith T2DM, but is related to apo 
B levels in the control group. Since the limi-
tation of this study �as the relatively small 
sample size, the study should be replicated 
�ith a larger sample. Increasing the sample 
size �ould improve the statistical po�er of 
the study to detect significant changes.
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